Terrie Curran insider trades
Open-market stock purchases and sales by Terrie Curran, Director at Arcutis Biotherapeutics, Inc, from SEC Form 4 filings since Nov 15, 2016.
Track record: 100% of 2 scored buys are up 5% or more since purchase, averaging +33%.